Discover selected EIC Pathfinder (TRL 1-3) and EIC Transition (TRL 4-6) projects in this latest ESIL e-Pitching session.
Date: 20 April 2026
Time: 4pm to 5:30pm CEST
Location: Online
What will we focus on?
Deep tech — research-based, science-driven solutions with strong technological content and long-term potential.
Within this broad deep-tech frame, we focus on healthcare, with selected projects specifically centered on biotechnology and medical devices.
Objective
Given the early stage of these projects, the objective of the pitches is not only to explore potential investment, but above all to identify opportunities for support along the journey from lab to market.
We aim for these sessions to spark meaningful conversations and collaborations between Business Angels, innovation actors and research teams, helping projects move forward through strategic guidance, partnerships and, where appropriate, future investment.
Who are we looking for?
Most of the projects could still be at an early stage of maturity, and they will benefit from your thoughtful feedback, guidance and support.
For this reason, we are especially interested in:
- Business angels looking to support the presented research teams in navigating their journey to market
- Patient early-stage funds who are open to following projects over time, not just looking for immediate deals
- Innovation actors and ecosystem players who want to engage with deep-tech research teams
Projects
Robiopsy
AI and Robotics for Prostate Biopsy
Robiopsy develops an AI-powered robotic platform to improve the accuracy and consistency of prostate biopsies. The system enhances cancer detection while reducing procedure variability.
Foresee
Novel microsensing platform for remote patient monitoring
FORESEE offers a novel implantable microsensing platform for enhanced remote monitoring of heart failure patients. The solution provides a complete view of the patient’s condition, supporting better patient management and clinical outcomes through patient- & event-specific proactive care
Response
Early detection of treatment response in breast cancer
RESPONSE focuses on enabling early assessment of treatment effectiveness through advanced imaging technologies. This approach supports more personalized therapies and faster clinical decision-making.
ACU-SERS
Automated clinical platform for personalised antibiotherapy in critical units based on surface enhancement raman spectroscopy
ACU-SERS develops an automated clinical platform for rapid sepsis detection using advanced spectroscopy. The solution enables faster diagnosis and improves outcomes in critical care settings.
PELVITRACK
PELVIc Floor Evaluation live TRACKing – Real-time prediction of perineal trauma
Pelvitrack provides a real-time multimodal system designed to anticipate the risk of perineal tearing during childbirth by supporting clinical decision-making throughout labour. Beyond the delivery setting, the technology also enables longitudinal monitoring of pelvic floor status across the life course, facilitating the early detection and management of pelvic health dysfunctions.
BREATH-SENSE
Miniaturised plasma emission spectroscopy-based breath analysis for unobtrusive at-home monitoring and prediction of COPD exacerbation
Breath-Sense creates miniaturised sensing devices for non-invasive breath analysis. The platform enables early detection and monitoring of diseases through simple, real-time measurements.
ISOS
Implantable Ecosystems of Genetically Modified Bacteria for the Personalised Treatment of Patients with Chronic Diseases
ISOS creates implantable ecosystems of engineered cells for long-term disease treatment. The platform enables adaptive and sustained therapeutic responses.